Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:33.091Z.
Calculation as of: 2026-10-06T13:30:33.091Z.
Quote observation: 2026-10-06T13:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8bc85e2d5351a47333dd9131f39a7cf6b6d5f02586c5202dd123a5ad4370615
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$108.94M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.17M
EV/EBIT Ratio
N/A
TTM Avg
21.29x
3Y Avg
21.29x
5Y Avg
21.29x
Market Cap
$107.58M
EV/EBIT Ratio
N/A
TTM Avg
56.93x
3Y Avg
94.02x
5Y Avg
53.96x
Market Cap
$115.55M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.99M
EV/EBIT Ratio
0.63x
TTM Avg
0.59x
3Y Avg
0.59x
5Y Avg
0.59x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $110.75M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.94M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 21.29x | 21.29x | 21.29x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.56M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.58M | N/A | 56.93x | 94.02x | 53.96x |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.55M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $102.99M | 0.63x | 0.59x | 0.59x | 0.59x |
| The Joint Corp. (JYNT)vs › | $102.43M | 57.35x | 89.36x | 94.92x | 1303.85x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
